BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Asgari S, Pournasr B, Salekdeh GH, Ghodsizadeh A, Ott M, Baharvand H. Induced pluripotent stem cells: A new era for hepatology. Journal of Hepatology 2010;53:738-51. [DOI: 10.1016/j.jhep.2010.05.009] [Cited by in Crossref: 54] [Cited by in F6Publishing: 52] [Article Influence: 4.5] [Reference Citation Analysis]
Number Citing Articles
1 Ooeda K, Kubiura-Ichimaru M, Tsuji S, Okuyama S, Yamashita M, Mine A, Kawamura F, Ueyama T, Tada M. A two-dimensional multiwell cell culture method for the production of CYP3A4-expressing hepatocyte-like cells from HepaRG cells. Pharmacol Res Perspect 2020;8:e00652. [PMID: 32955797 DOI: 10.1002/prp2.652] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
2 Bishi DK, Mathapati S, Cherian KM, Guhathakurta S, Verma RS. In vitro hepatic trans-differentiation of human mesenchymal stem cells using sera from congestive/ischemic liver during cardiac failure. PLoS One 2014;9:e92397. [PMID: 24642599 DOI: 10.1371/journal.pone.0092397] [Cited by in Crossref: 8] [Cited by in F6Publishing: 7] [Article Influence: 1.0] [Reference Citation Analysis]
3 Heydari Z, Najimi M, Mirzaei H, Shpichka A, Ruoss M, Farzaneh Z, Montazeri L, Piryaei A, Timashev P, Gramignoli R, Nussler A, Baharvand H, Vosough M. Tissue Engineering in Liver Regenerative Medicine: Insights into Novel Translational Technologies. Cells 2020;9:E304. [PMID: 32012725 DOI: 10.3390/cells9020304] [Cited by in Crossref: 16] [Cited by in F6Publishing: 12] [Article Influence: 8.0] [Reference Citation Analysis]
4 Jazaeri F, Sheibani M, Nezamoleslami S, Moezi L, Dehpour AR. Current Models for Predicting Drug-induced Cholestasis: The Role of Hepatobiliary Transport System. Iran J Pharm Res 2021;20:1-21. [PMID: 34567142 DOI: 10.22037/ijpr.2020.113362.14254] [Reference Citation Analysis]
5 Asgari S, Moslem M, Bagheri-Lankarani K, Pournasr B, Miryounesi M, Baharvand H. Differentiation and transplantation of human induced pluripotent stem cell-derived hepatocyte-like cells. Stem Cell Rev. 2013;9:493-504. [PMID: 22076752 DOI: 10.1007/s12015-011-9330-y] [Cited by in Crossref: 63] [Cited by in F6Publishing: 59] [Article Influence: 7.9] [Reference Citation Analysis]
6 Busletta C, Novo E, Parola M. Human-induced pluripotent stem cells as a source of hepatocyte-like cells: new kids on the block. Hepatol Int 2013;7:299-305. [DOI: 10.1007/s12072-011-9300-0] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 0.3] [Reference Citation Analysis]
7 Anene-nzelu C, Wang Y, Yu H, Liang LH. LIVER TISSUE MODEL FOR DRUG TOXICITY SCREENING. J Mech Med Biol 2011;11:369-90. [DOI: 10.1142/s0219519411004083] [Cited by in Crossref: 3] [Article Influence: 0.3] [Reference Citation Analysis]
8 Vosough M, Moslem M, Pournasr B, Baharvand H. Cell-based therapeutics for liver disorders. Br Med Bull 2011;100:157-72. [PMID: 21771778 DOI: 10.1093/bmb/ldr031] [Cited by in Crossref: 24] [Cited by in F6Publishing: 26] [Article Influence: 2.2] [Reference Citation Analysis]
9 Fang YL, Chen XG, W T G. Gene delivery in tissue engineering and regenerative medicine. J Biomed Mater Res B Appl Biomater 2015;103:1679-99. [PMID: 25557560 DOI: 10.1002/jbm.b.33354] [Cited by in Crossref: 15] [Cited by in F6Publishing: 8] [Article Influence: 1.9] [Reference Citation Analysis]
10 Liu Z, Zhou J, Wang H, Zhao M, Wang C. Current status of induced pluripotent stem cells in cardiac tissue regeneration and engineering. Regen Med Res 2013;1:6. [PMID: 25984325 DOI: 10.1186/2050-490X-1-6] [Cited by in Crossref: 12] [Cited by in F6Publishing: 8] [Article Influence: 1.3] [Reference Citation Analysis]
11 Chaudhari P, Tian L, Kim A, Zhu Q, Anders R, Schwarz KB, Sharkis S, Ye Z, Jang YY. Transient c-Src Suppression During Endodermal Commitment of Human Induced Pluripotent Stem Cells Results in Abnormal Profibrotic Cholangiocyte-Like Cells. Stem Cells 2019;37:306-17. [PMID: 30471152 DOI: 10.1002/stem.2950] [Cited by in Crossref: 4] [Cited by in F6Publishing: 6] [Article Influence: 1.0] [Reference Citation Analysis]
12 Pareja E, Gómez-Lechón MJ, Tolosa L. Induced pluripotent stem cells for the treatment of liver diseases: challenges and perspectives from a clinical viewpoint. Ann Transl Med 2020;8:566. [PMID: 32775367 DOI: 10.21037/atm.2020.02.164] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
13 Vercauteren K, de Jong YP, Meuleman P. HCV animal models and liver disease. J Hepatol 2014;61:S26-33. [PMID: 25443343 DOI: 10.1016/j.jhep.2014.07.013] [Cited by in Crossref: 32] [Cited by in F6Publishing: 30] [Article Influence: 4.0] [Reference Citation Analysis]
14 Liu Z, Tang Y, Lü S, Zhou J, Du Z, Duan C, Li Z, Wang C. The tumourigenicity of iPS cells and their differentiated derivates. J Cell Mol Med 2013;17:782-91. [PMID: 23711115 DOI: 10.1111/jcmm.12062] [Cited by in Crossref: 62] [Cited by in F6Publishing: 60] [Article Influence: 6.9] [Reference Citation Analysis]
15 Greenhough S, Hay DC. Stem Cell-Based Toxicity Screening: Recent Advances in Hepatocyte Generation. Pharm Med 2012;26:85-9. [DOI: 10.1007/bf03256896] [Cited by in Crossref: 8] [Article Influence: 0.8] [Reference Citation Analysis]
16 Lu X, Liu L, Shan W, Kong L, Chen N, Lou Y, Zeng S. The Role of the Sodium-taurocholate Co-transporting Polypeptide (NTCP) and Bile Salt Export Pump (BSEP) in Related Liver Disease. Curr Drug Metab 2019;20:377-89. [PMID: 31258056 DOI: 10.2174/1389200220666190426152830] [Cited by in Crossref: 6] [Cited by in F6Publishing: 5] [Article Influence: 2.0] [Reference Citation Analysis]
17 Yao J, Yu Y, Nyberg SL. Induced Pluripotent Stem Cells for the Treatment of Liver Diseases: Novel Concepts. Cells Tissues Organs 2020;:1-17. [PMID: 32615573 DOI: 10.1159/000508182] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 2.0] [Reference Citation Analysis]
18 Liu Z, Wen X, Wang H, Zhou J, Zhao M, Lin Q, Wang Y, Li J, Li D, Du Z, Yao A, Cao F, Wang C. Molecular imaging of induced pluripotent stem cell immunogenicity with in vivo development in ischemic myocardium. PLoS One 2013;8:e66369. [PMID: 23840453 DOI: 10.1371/journal.pone.0066369] [Cited by in Crossref: 13] [Cited by in F6Publishing: 11] [Article Influence: 1.4] [Reference Citation Analysis]
19 Rodriguez-Osorio N, Urrego R, Cibelli JB, Eilertsen K, Memili E. Reprogramming mammalian somatic cells. Theriogenology 2012;78:1869-86. [PMID: 22979962 DOI: 10.1016/j.theriogenology.2012.05.030] [Cited by in Crossref: 70] [Cited by in F6Publishing: 65] [Article Influence: 7.0] [Reference Citation Analysis]
20 Pietronave S, Prat M. Advances and applications of induced pluripotent stem cells. Can J Physiol Pharmacol 2012;90:317-25. [DOI: 10.1139/y11-125] [Cited by in Crossref: 8] [Cited by in F6Publishing: 7] [Article Influence: 0.8] [Reference Citation Analysis]
21 Gao X, Liu Y. A transcriptomic study suggesting human iPSC-derived hepatocytes potentially offer a better in vitro model of hepatotoxicity than most hepatoma cell lines. Cell Biol Toxicol 2017;33:407-21. [PMID: 28144825 DOI: 10.1007/s10565-017-9383-z] [Cited by in Crossref: 45] [Cited by in F6Publishing: 42] [Article Influence: 9.0] [Reference Citation Analysis]
22 Li YS, Harn HJ, Hsieh DK, Wen TC, Subeq YM, Sun LY, Lin SZ, Chiou TW. Cells and materials for liver tissue engineering. Cell Transplant. 2013;22:685-700. [PMID: 23127824 DOI: 10.3727/096368912x655163] [Cited by in Crossref: 23] [Cited by in F6Publishing: 10] [Article Influence: 2.3] [Reference Citation Analysis]
23 Yu Y, Wang X, Nyberg SL. Potential and Challenges of Induced Pluripotent Stem Cells in Liver Diseases Treatment. J Clin Med 2014;3:997-1017. [PMID: 26237490 DOI: 10.3390/jcm3030997] [Cited by in Crossref: 18] [Cited by in F6Publishing: 17] [Article Influence: 2.3] [Reference Citation Analysis]
24 Ghodsizadeh A, Taei A, Totonchi M, Seifinejad A, Gourabi H, Pournasr B, Aghdami N, Malekzadeh R, Almadani N, Salekdeh GH. Generation of liver disease-specific induced pluripotent stem cells along with efficient differentiation to functional hepatocyte-like cells. Stem Cell Rev. 2010;6:622-632. [PMID: 20821352 DOI: 10.1007/s12015-010-9189-3.] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
25 Greenhough S, Medine CN, Hay DC. Pluripotent stem cell derived hepatocyte like cells and their potential in toxicity screening. Toxicology. 2010;278:250-255. [PMID: 20674645 DOI: 10.1016/j.tox.2010.07.012] [Cited by in Crossref: 51] [Cited by in F6Publishing: 41] [Article Influence: 4.3] [Reference Citation Analysis]
26 Ghodsizadeh A, Taei A, Totonchi M, Seifinejad A, Gourabi H, Pournasr B, Aghdami N, Malekzadeh R, Almadani N, Salekdeh GH. Generation of liver disease-specific induced pluripotent stem cells along with efficient differentiation to functional hepatocyte-like cells. Stem Cell Rev. 2010;6:622-632. [PMID: 20821352 DOI: 10.1007/s12015-010-9189-3] [Cited by in Crossref: 118] [Cited by in F6Publishing: 94] [Article Influence: 10.7] [Reference Citation Analysis]
27 Hannoun Z, Steichen C, Dianat N, Weber A, Dubart-Kupperschmitt A. The potential of induced pluripotent stem cell derived hepatocytes. J Hepatol. 2016;65:182-199. [PMID: 26916529 DOI: 10.1016/j.jhep.2016.02.025] [Cited by in Crossref: 57] [Cited by in F6Publishing: 57] [Article Influence: 9.5] [Reference Citation Analysis]
28 Jozefczuk J, Prigione A, Chavez L, Adjaye J. Comparative Analysis of Human Embryonic Stem Cell and Induced Pluripotent Stem Cell-Derived Hepatocyte-Like Cells Reveals Current Drawbacks and Possible Strategies for Improved Differentiation. Stem Cells and Development 2011;20:1259-75. [DOI: 10.1089/scd.2010.0361] [Cited by in Crossref: 55] [Cited by in F6Publishing: 50] [Article Influence: 5.0] [Reference Citation Analysis]
29 Medine CN, Lucendo-Villarin B, Zhou W, West CC, Hay DC. Robust generation of hepatocyte-like cells from human embryonic stem cell populations. J Vis Exp 2011;:e2969. [PMID: 22064456 DOI: 10.3791/2969] [Cited by in Crossref: 8] [Cited by in F6Publishing: 12] [Article Influence: 0.7] [Reference Citation Analysis]
30 Krishna KA, Krishna KS, Berrocal R, Tummala A, Rao KS, Rao KR. A review on the therapeutic potential of embryonic and induced pluripotent stem cells in hepatic repair. J Nat Sci Biol Med 2011;2:141-4. [PMID: 22346225 DOI: 10.4103/0976-9668.92314] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 0.4] [Reference Citation Analysis]
31 Yang D, Wang ZQ, Deng JQ, Liao JY, Wang X, Xie J, Deng MM, Lü MH. Adipose-derived stem cells: A candidate for liver regeneration. J Dig Dis 2015;16:489-98. [PMID: 26121206 DOI: 10.1111/1751-2980.12268] [Cited by in Crossref: 10] [Cited by in F6Publishing: 9] [Article Influence: 1.7] [Reference Citation Analysis]
32 Nicolas C, Wang Y, Luebke-Wheeler J, Nyberg SL. Stem Cell Therapies for Treatment of Liver Disease. Biomedicines 2016;4:E2. [PMID: 28536370 DOI: 10.3390/biomedicines4010002] [Cited by in Crossref: 22] [Cited by in F6Publishing: 17] [Article Influence: 3.7] [Reference Citation Analysis]
33 Okuyama S, Kawamura F, Kubiura M, Tsuji S, Osaki M, Kugoh H, Oshimura M, Kazuki Y, Tada M. Real-time fluorometric evaluation of hepatoblast proliferation in vivo and in vitro using the expression of CYP3A7 coding for human fetus-specific P450. Pharmacol Res Perspect 2020;8:e00642. [PMID: 32886454 DOI: 10.1002/prp2.642] [Cited by in Crossref: 1] [Cited by in F6Publishing: 3] [Article Influence: 1.0] [Reference Citation Analysis]
34 Stieger B, Geier A. Genetic variations of bile salt transporters as predisposing factors for drug-induced cholestasis, intrahepatic cholestasis of pregnancy and therapeutic response of viral hepatitis. Expert Opin Drug Metab Toxicol 2011;7:411-25. [PMID: 21320040 DOI: 10.1517/17425255.2011.557067] [Cited by in Crossref: 40] [Cited by in F6Publishing: 33] [Article Influence: 3.6] [Reference Citation Analysis]
35 Idriss S, Zibara K, Cariou B, Si-tayeb K. From Human-Induced Pluripotent Stem Cells to Liver Disease Modeling: A Focus on Dyslipidemia. Curr Pathobiol Rep 2015;3:47-56. [DOI: 10.1007/s40139-015-0067-1] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.1] [Reference Citation Analysis]
36 Pan X, Li L. Advances in cell sources of hepatocytes for bioartificial liver. Hepatobiliary & Pancreatic Diseases International 2012;11:594-605. [DOI: 10.1016/s1499-3872(12)60230-6] [Cited by in Crossref: 16] [Cited by in F6Publishing: 6] [Article Influence: 1.6] [Reference Citation Analysis]
37 Roy-Chowdhury N, Wang X, Guha C, Roy-Chowdhury J. Hepatocyte-like cells derived from induced pluripotent stem cells. Hepatol Int. 2017;11:54-69. [PMID: 27530815 DOI: 10.1007/s12072-016-9757-y] [Cited by in Crossref: 23] [Cited by in F6Publishing: 20] [Article Influence: 3.8] [Reference Citation Analysis]
38 Ni Y, Urban S. Stem cell-derived hepatocytes: A promising novel tool to study hepatitis B virus infection. J Hepatol 2017;66:473-5. [PMID: 27965155 DOI: 10.1016/j.jhep.2016.11.027] [Cited by in Crossref: 4] [Cited by in F6Publishing: 5] [Article Influence: 0.7] [Reference Citation Analysis]
39 Yi F, Liu GH, Izpisua Belmonte JC. Human induced pluripotent stem cells derived hepatocytes: rising promise for disease modeling, drug development and cell therapy. Protein Cell 2012;3:246-50. [PMID: 22441839 DOI: 10.1007/s13238-012-2918-4] [Cited by in Crossref: 41] [Cited by in F6Publishing: 38] [Article Influence: 4.1] [Reference Citation Analysis]
40 Mobarra N, Raji S, Najafi S, Kafi FK, Ferns GA, Pakzad R. Hypoxia-Induced miR-210 Overexpression Promotes the Differentiation of Human-Induced Pluripotent Stem Cells to Hepatocyte-Like Cells on Random Nanofiber Poly-L-Lactic Acid/Poly (ε-Caprolactone) Scaffolds. Oxid Med Cell Longev 2021;2021:4229721. [PMID: 34858546 DOI: 10.1155/2021/4229721] [Reference Citation Analysis]
41 Sangan CB, Tosh D. Hepatic progenitor cells. Cell Tissue Res. 2010;342:131-137. [PMID: 20957497 DOI: 10.1007/s00441-010-1055-8] [Cited by in Crossref: 13] [Cited by in F6Publishing: 6] [Article Influence: 1.1] [Reference Citation Analysis]
42 Noor F. A shift in paradigm towards human biology-based systems for cholestatic-liver diseases. J Physiol 2015;593:5043-55. [PMID: 26417843 DOI: 10.1113/JP271124] [Cited by in Crossref: 13] [Cited by in F6Publishing: 5] [Article Influence: 1.9] [Reference Citation Analysis]
43 Yu Y, Wang X, Nyberg SL. Application of Induced Pluripotent Stem Cells in Liver Diseases. Cell Med 2014;7:1-13. [PMID: 26858888 DOI: 10.3727/215517914X680056] [Cited by in Crossref: 10] [Cited by in F6Publishing: 7] [Article Influence: 1.3] [Reference Citation Analysis]
44 Yuan L, Zhang Y, Liu X, Chen Y, Zhang L, Cao J, Li X, Wang M, Wu K, Zhang J, Liu G, Tang Q, Yuan Q, Cheng T, Xia N. Agonist c-Met Monoclonal Antibody Augments the Proliferation of hiPSC-derived Hepatocyte-Like Cells and Improves Cell Transplantation Therapy for Liver Failure in Mice. Theranostics 2019;9:2115-28. [PMID: 31037160 DOI: 10.7150/thno.30009] [Cited by in Crossref: 8] [Cited by in F6Publishing: 8] [Article Influence: 2.7] [Reference Citation Analysis]
45 Zhang M, Zhong Y, Chen J. Model systems and clinical applications of hepatic stem cells for liver regeneration. Hepatol Int 2012;6:564-75. [DOI: 10.1007/s12072-011-9323-6] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.1] [Reference Citation Analysis]
46 Csöbönyeiová M, Polák Š, Danišovič L. Toxicity testing and drug screening using iPSC-derived hepatocytes, cardiomyocytes, and neural cells. Can J Physiol Pharmacol 2016;94:687-94. [PMID: 27128322 DOI: 10.1139/cjpp-2015-0459] [Cited by in Crossref: 23] [Cited by in F6Publishing: 13] [Article Influence: 3.8] [Reference Citation Analysis]
47 Aravalli RN, Cressman EN, Steer CJ. Hepatic differentiation of porcine induced pluripotent stem cells in vitro. The Veterinary Journal 2012;194:369-74. [DOI: 10.1016/j.tvjl.2012.05.013] [Cited by in Crossref: 28] [Cited by in F6Publishing: 24] [Article Influence: 2.8] [Reference Citation Analysis]
48 Vessoni AT, Muotri AR, Okamoto OK. Autophagy in stem cell maintenance and differentiation. Stem Cells Dev 2012;21:513-20. [PMID: 22066548 DOI: 10.1089/scd.2011.0526] [Cited by in Crossref: 101] [Cited by in F6Publishing: 93] [Article Influence: 10.1] [Reference Citation Analysis]
49 Kumar A, Pati NT, Sarin SK. Use of stem cells for liver diseases-current scenario. J Clin Exp Hepatol 2011;1:17-26. [PMID: 25755306 DOI: 10.1016/S0973-6883(11)60114-X] [Cited by in Crossref: 5] [Cited by in F6Publishing: 2] [Article Influence: 0.5] [Reference Citation Analysis]
50 Vosough M, Omidinia E, Kadivar M, Shokrgozar MA, Pournasr B, Aghdami N, Baharvand H. Generation of functional hepatocyte-like cells from human pluripotent stem cells in a scalable suspension culture. Stem Cells Dev 2013;22:2693-705. [PMID: 23731381 DOI: 10.1089/scd.2013.0088] [Cited by in Crossref: 77] [Cited by in F6Publishing: 75] [Article Influence: 8.6] [Reference Citation Analysis]
51 Giri S, Bader A. Improved preclinical safety assessment using micro-BAL devices: the potential impact on human discovery and drug attrition. Drug Discov Today 2011;16:382-97. [PMID: 21354326 DOI: 10.1016/j.drudis.2011.02.012] [Cited by in Crossref: 11] [Cited by in F6Publishing: 11] [Article Influence: 1.0] [Reference Citation Analysis]
52 de Lima Toccafondo Vieira M, Tagliati CA. Hepatobiliary transporters in drug-induced cholestasis: a perspective on the current identifying tools. Expert Opin Drug Metab Toxicol 2014;10:581-97. [PMID: 24588537 DOI: 10.1517/17425255.2014.884069] [Cited by in Crossref: 24] [Cited by in F6Publishing: 20] [Article Influence: 3.0] [Reference Citation Analysis]
53 Fattahi F, Asgari S, Pournasr B, Seifinejad A, Totonchi M, Taei A, Aghdami N, Salekdeh GH, Baharvand H. Disease-corrected hepatocyte-like cells from familial hypercholesterolemia-induced pluripotent stem cells. Mol Biotechnol. 2013;54:863-873. [PMID: 23247991 DOI: 10.1007/s12033-012-9635-3] [Cited by in Crossref: 30] [Cited by in F6Publishing: 25] [Article Influence: 3.3] [Reference Citation Analysis]